Integrative proteomic profiling of tumor and plasma extracellular vesicles identifies a diagnostic biomarker panel for colorectal cancer
Quick Facts
- Publication title: Integrative proteomic profiling of tumor and plasma extracellular vesicles identifies a diagnostic biomarker panel for colorectal cancer
- Journal: Cell Rep Med
- Year: 2025
- DOI: 10.1016/j.xcrm.2025.102090
- PMID/PMCID: 40311616; PMC12147850
Research overview
The lack of reliable non-invasive biomarkers for early colorectal cancer (CRC) diagnosis underscores the need for improved diagnostic tools. Our analysis of EV protein profiles from tissue and plasma demonstrates ColonTrack's potential as a robust non-invasive biomarker panel for CRC diagnosis and early detection.
Key findings
The lack of reliable non-invasive biomarkers for early colorectal cancer (CRC) diagnosis underscores the need for improved diagnostic tools.
Extracellular vesicles (EVs) have emerged as promising candidates for liquid-biopsy-based cancer monitoring.
Here, we propose a comprehensive workflow that integrates staged mass spectrometry (MS)-based discovery and verification with ELISA-based validation to identify EV protein biomarkers for CRC.
Our approach, applied to 1,272 individuals, yields a machine learning model, ColonTrack, incorporating EV proteins HNRNPK, CTTN, and PSMC6.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Tissue EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Integrative proteomic profiling of tumor and plasma extracellular vesicles identifies a diagnostic biomarker panel for colorectal cancer Cell reports Medicine. 2025. DOI: 10.1016/j.xcrm.2025.102090. PMID/PMCID: 40311616; PMC12147850.